Mereo Biopharma Group Plc ADR (MREO) Implied Volatility Current

Tracking MREO implied volatility helps you identify when options premiums on Mereo Biopharma Group Plc ADR are historically cheap or expensive, and where the best trades are hiding. Mereo Biopharma Group Plc ADR implied volatility reflects the market's expectation of future price movement: when MREO IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Mereo Biopharma Group Plc ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For MREO, tracking metrics like MREO IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on MREO signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism.

In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where MREO implied volatility sits today versus where it has been. Our scanner ranks Mereo Biopharma Group Plc ADR implied volatility against its historical range, surfaces extremes in MREO IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Mereo Biopharma Group Plc ADR IV is rich or cheap — measure it, then act on it.